Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 15, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory notification of share transactions and does not contain financial performance data.
Material Changes
The material change reported is a transfer of 865,298 Ordinary Shares from the GlaxoSmithKline Employee Trust ("the GSK Trust") to participants in the SmithKline Beecham Employee Share Option Plan 1991. This transaction occurred on November 14, 2005, and was advised to the company on November 15, 2005.
Outlook, Risks, and Management Commentary
The filing notes that the GSK Trust is a discretionary trust where all current and former employees are potential beneficiaries. Three directors (Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop) hold interests in the shares held by the trust in the same capacity as other employees. No specific guidance, outlook, or risk factors regarding business operations are provided in this text.
Key Facts for Investor Verification
- 865,298 Ordinary Shares were transferred from the GSK Trust to employee plan participants.
- The transaction relates to the SmithKline Beecham Employee Share Option Plan 1991.
- Three directors have an indirect interest in the trust shares as potential beneficiaries.
- This filing does not contain financial results or operational updates.